Cartalax
Peptide bioregulator developed by Vladimir Khavinson targeting cartilage tissue. Studied for organ-specific gene expression normalisation and age-related
Anti-AgingRecovery
● In Stock
Buy more, save more
—
1+ vials
−5%
3+ vials
−10%
5+ vials
−20%
10+ vials
Total Price
$180
For research & laboratory use only. Not for human consumption.
Administration Route
Subcutaneous injection
Cartilage Peptide
Khavinson tetrapeptide targeting chondrocyte gene expression
Joint Ageing
Supports collagen II synthesis in ageing cartilage
Arthritis Research
Potential to slow cartilage degradation in OA models
Effect Profile
Based on primary research mechanisms
Cellular Longevity
0%
Collagen Synthesis
0%
Oxidative Protection
0%
Energy Restoration
0%
Mechanism of Action
Cartalax is a short peptide bioregulator from the Khavinson series, designed to act as a complementary DNA sequence that penetrates cell nuclei and binds to gene promoter regions controlling chondrocyte proliferation, cartilage matrix production, and articular joint tissue maintenance. By interacting with nuclear chromatin, it normalises the expression of genes involved in cell cycle regulation and tissue homeostasis, correcting age-associated downregulation of maintenance programmes in the target tissue.
Scientific Research
1
Peptide regulation of aging in cartilage tissue and anti-aging bioregulators
Annals of the New York Academy of Sciences (2005)